



Novel Therapeutic Targets for the Treatment of Multiple Myeloma

Guest Editor:

Dr. Ilaria Saltarella

Section of Pharmacology,
Department of Precision and
Regenerative Medicine and
Jonian Area, School of Medicine,
University of Bari Aldo Moro,
70124 Bari, Italy

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editor

Dear Colleagues,

Multiple myeloma progression and drug resistance strongly depends on the crosstalk between tumor plasma cells and the surrounding microenvironment, highlighting the importance of target tumor plasma cells and the bone marrow microenvironment. Despite the therapeutic progress, multiple myeloma is still an incurable malignancy, and many patients undergo drug resistance or relapse.

This Special Issue will focus on the recent advances in the field of multiple myeloma: novel therapeutic targets, conventional drugs, as well as innovative cell- and RNA-based therapies, with the aim of improving patient outcome and overall survival.

In this Special Issue, original research articles and reviews are welcome.

Dr. Ilaria Saltarella
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)